Multi-drug resistance in chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 34, Issue 1-2, 1999, Pages 171-178

  Friedenberg, William R ^a,d   Spencer, Susan K ^a   Musser, Cynthia ^a   Hogan, Thomas F ^b   Rodvold, Keith A ^c   Rushing, Daniel A ^a   Mazza, Joseph J ^a   Tewksbury, Duane A ^a   Marx, James J ^a  

^a MARSHFIELD CLINIC   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d GUTHRIE RESEARCH INSTITUTE   (United States)

Author keywords

Chronic lymphocytic leukemia; Multi drug resistance; P gp 170 (p glycoprotein); PSC 833

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CYCLOSPORIN A; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MRK 16; VALSPODAR; VINCRISTINE;

ARTICLE; ASSAY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CYTOTOXICITY; DRUG RETENTION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0033036047     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199909083394     Document Type: Article

References (58)

1. Curt, G. A., Clendeninn, N. J. and Chabner, B. A. (1984). Drug resistance in cancer. Cancer Treatment Reports, 68, 87-99.
2. Goldie, J. H. and Coldman, A. J. (1979). A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treatment Reports, 63, 1727-1733.
3. Riordan, J. R. and Ling, V. (1985). Genetic and biochemical characterization of multidrug resistance. Pharmacology and Therapeutics, 28, 51-75.
4. Pastan, I. and Gottesman, M. (1987). Multiple-drug resistance in human cancer. New England Journal of Medicine, 316, 1388-1393.
5. Hochhauser, D. and Harris, A. L. (1991). Mechanisms of multi-drug resistance. In: Haematological Oncology, A. Newland, A. Burnett, A. Keating and J. Armitage, (eds.), vol. 1, pp 29-48, (Cambridge University Press, United Kingdom).
6. Beck, W. T. (1991). Modulators of p-glycoprotein associated multidrug resistance. In: Drug Resistance, R. F. Ozols (ed.), (Kluwer Academic Publishers, Norwell, MA).
7. Dalton, W. S. and Grogan, T. M. (1991). Does P-glycoprotein predict response to chemotherapy, and if so, is there a reliable way to detect it? Journal of the National Cancer Institute, 83, 80-81.
8. Dohner, H., Fischer, K., Bentz, M., Hansen, K., Benner, A., Cabot, G., Diehl, D., Schlenk, R., Coy, J., Stilgenbauer, S., Volkmann, M., Galle, P. R., Poustka, A., Hunstein, W. and Lichter, P. (1995). p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood, 85, 1580-1589.
9. Benchimol, S. and Ling, V. (1994). P-glycoprotein and tumor progression. Journal of the National Cancer Institute, 86, 814-816.
10. Braverman, A. S. (1993). Chemotherapeutic failure: Resistance or insensitivity? Annals of Internal Medicine, 118, 630-632.
11. O'Brien, S., del Giglio, A. and Keating, M. (1995). Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood, 85, 307-318.
12. Faguet, G. B. (1994). Chronic lymphocytic leukemia: An updated review. Journal of Clinical Oncology, 12, 1974-1990.
13. Marie, J. P. (1995). P-glycoprotein in adult hematologic malignancies. Hematology/Oncology Clinics of North America, 9, 239-249.
14. Ford, J. M. (1995). Modulators of multidrug resistance: Pre-clinical studies. Hematology/Oncology Clinics of North America, 9, 337-361.
15. Slater, L. M., Sweet, P., Stupecky, M. and Gupta, S. (1986). Cyclosporine A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. Journal of Clinical Investigation, 77, 1405-1408.
16. Osieka, R., Seeber, S., Pannenbacker, R., Soll, D., Glatte, P. and Schmidt, C.G. (1986). Enhancement of etoposide-induced cytotoxicity by cyclosporine A. Cancer Chemotherapy and Pharmacology, 18, 198-202.
17. Nooter, K., Sonneveld, P., Oostrum, R., Herweijer, H., Hagenbeek, T. and Valerio, D. (1990). Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporine-A. International Journal of Cancer., 45, 263-268.
18. Salmon, S. E., Dalton, W. S., Grogan, T. M., Plezia, P., Lehnert, M., Roe, D. J. and Miller, T. P. (1991). Multidrug-resistant myeloma. Laboratory and clinical effects of chemosensitizers. Blood, 78, 44-50.
19. Herweijer, H., Sonneveld, P., Baas, F. and Nooter, K. (1990). Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation by cyclosporine. Journal of the National Cancer Institute, 82, 1133-1140.
20. Sonneveld, P. and Nooter, K. (1990). Reversal of drug-resistance by cyclosporine-A in a patient with acute myelocytic leukaemia. British Journal of Haematology. 75, 208-211.
21. Twemyman, P. R., Wright, K. A. and Wallace, H. M. (1989) Cyclosporine-A and non-immunosuppressive analogs inhibit growth of human lung cancer cells in vitro. Proceedings of the American Association of Clinical Research, 30, 483.
22. Jonsson, B., Nilsson, K., Nygren, P. and Larsson, R. (1992). SDZ PSC-833, a novel potent in vitro chemosensitizer in multiple myeloma. Anticancer Drugs, 3, 641-646.
23. Jaffrezou, J. P., Sikic, B. I. and Laurent, G. (1994). Cyclosporine-A and cyclosporine SDZ PSC-833 enhance anti-CD5 ricin A-chain immunotoxins in human leukemic T cells. Blood, 83, 482-489.
24. Sonneveld, P., Marie, J. P., Lokhorst, H. M., Nooter, K. and Schoester, M. (1994). Clinical modulation of multidrug resistance in VAD-refractory multiple myeloma: studies with cyclosporine and SDZ PSC-833. Anticancer Drugs, 5, 72.
25. Erlichman, C., Moore, M., Thiessen, J., De Angelis, C., Goodman, P. and Manzo, J. (1994). A phase I trial of doxorubicin (DOX) and PSC-833, a modulator of multidrug resistance (MDR). Anticancer Drugs, 5, 42.
26. Giaccone, G., Linn, S. C., Catimel, G., Dumortier, A., Foy, M., Vermorken, J. B., Koier, I., Welink, J., van der Vijgh, W. J. F., Eeltink, C., Laburte, C. and Pinedo, H. M. (1994). SDZ PSC-833 in combination with doxorubicin: A phase I and pharmacologic study in solid tumors. Anticancer Drugs, 5, 42.
27. R) (T) in combination with SDZ PSC-833, a potent modulator of multidrug resistance (MDR). Anticancer Drugs, 5, 43.
28. Erlichman, C., Moore, M. J., De Angelis, C., Goodman, P. and Manzo, J. (1994). The pharmacokinetics and bioavailability of a new chemosensitizer, SDZ PSC-833, in patients with advanced cancer. Anticancer Drugs, 5, 44.
29. Lum, B. L., Fisher, G. A., Hausdorff, J., Halsey, J., Collins, H., Brophy, N. A., Ehsan, M. N. and Sikic, B. I. (1994). The effect of oral SDZ PSC-833 on the pharmacokinetics (PK) of etoposide (E) during a phase I trial to modulate multidrug resistance. Anticancer Drugs, 5, 44.
30. Twentyman, P. R. and Bleehen, N. M. (1991). Resistance modification by PSC-833, a novel nonimmunosuppressive Cyclosporine-A. European Journal of Cancer, 27, 1639-1642.
31. Boesch, D., Gaveriaux, C., Jachez, B., Pourtier-Manzanedo, A., Bollinger, P. and Loor, F. (1991). In vivo circumvention of P glycoprotein mediated multidrug resistance of tumor cells with SDZ PSC-833. Cancer Research, 51, 4226-4233.
32. Schrek, R. (1988). Chronic lymphocytic leukemic patients, resistant to chemotherapy. Medical Hypotheses, 26, 277-288.
33. Cumber, P. M., Jacobs, A., Hoy, T., Fisher, J., Whittaker, J. A., Tsuruo, T. and Padua, R. A. (1990). Expression of the multiple drug resistance gene (MDR-1) and epitope masking in chronic lymphatic leukaemia. British Journal of Haematology, 76, 226-230.
34. Shustik, C., Groulx, N. and Gros, P. (1991). Analysis of multidrug resistance (MDR-1) gene expression in chronic lymphocytic leukaemia (CLL). British Journal of Haematology, 79, 50-56.
35. 3 multidrug-resistance gene in advanced-stage chronic lymphocytic leukemia. Blood, 79, 1496-1500.
36. El Rouby, S., Thomas, A., Costin, D., Rosenberg, C. R., Potmesil, M., Silber, R. and Newcomb, E. W. (1993). p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood, 82, 3452-3459.
37. Holmes, J. A., Jacobs, A., Carter, G., Whittaker, J. A., Bentley, D. P. and Padua, R. A. (1990). Is the MDRI gene relevant in chronic lymphocytic leukemia? Leukemia, 4, 216-218.
38. Michieli, M., Raspadori, D., Damiani, D., Geromin, A., Gallizia, C., Michelutti, A., Fanin, R., Fasola, G., Russo, D., Tazzari, P., Pileri, S., Mallardi, F. and Baccarani, M. (1991). The expression of the multidrug resistance-associated glycoprotein in B-cell chronic lymphocytic leukaemia. British Journal of Haematology, 77, 460-465.
39. Ludescher, C., Hilbe, W., Eisterer, W., Preuss, E., Huber, C., Gotwald, M., Hofmann, J. and Thaler, J. (1993). Activity of P-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay. Journal of the National Cancer Institute, 85, 1751-1758.
40. Sparrow, R. L., Hall, F. J., Siregar, H. and Van der Weyden, M. B. (1993). Common expression of the multidrug resistance marker P-glycoprotein in B-cell chronic lymphocytic leukaemia and correlation with in vitro drug resistance. Leukemia Research, 17, 941-947.
41. Beck, W. T., Grogan, T. M., Willman, C. L., Cordon-Cardo, C., Parham, D. M., Kuttesch, J. F., Andreeff, M., Bates, S. E., Berard, C. W., Boyett, J. M., Brophy, N. A., Broxterman, H. J., Chan, H. S., Dalton, W. S., Dietel, M., Fojo, A. T., Gascoyne, R. D., Head, D., Houghton, P. J., Scrivastava, D. K., Lehnert, M., Leith, C. P., Paietta, E., Pavelic, Z. P. and Weinstein, R. (1996). Methods to detect p-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations. Cancer Research, 56, 3010-3020.
42. Cheson, B. D., Bennett, J. M., Grever, M., Kay, N., Keating, M. J., O'Brien, S. and Rai, K. R. (1996). National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood, 87, 4990-4997.
43. Bruno, N. A. and Slate, D. L. (1990). Effect of exposure to calcium entry blockers on doxorubicin accumulation and cytotoxicity in multidrug-resistant cells. Journal of the National Cancer Institute, 82, 419-424.
44. Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of Immunological Methods, 65, 55-63.
45. Grogan, T., Dalton, W., Rybaki, J., Spier, C., Meltzer, P., Richter, L., Gleason, M., Pindur, J., Cline, A., Scheper, R., Tsuruo, T., and Salmon, S. (1990). Optimization of immunocytochemical P-glycoprotein assessment in multidrug resistant plasma cell myeloma using three antibodies. Laboratory Investigation, 63, 815-824.
46. Broxterman, H. J., Sonneveld, P., Feller, N., Ossenkoppele, G. J., Wahrer, D. C., Eekman, C. A., Schoester, M., Lankelma, J., Pinedo, H. M., Lowenberg, B. and Schuurhuis, G. J. (1996). Quality control of multidrug resistance assays in adult acute leukemia: Correlation between assays for p-glycoprotein expression and activity. Blood, 87, 4809-4816.
47. - cases. Blood, 86, 2329-2342.
48. Abbaszadegan, M. R., Futscher, B. W., Klimecki, W. T., List, A. and Dalton, W. S. (1994). Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells. Cancer Research, 54, 4676-4679.
49. Gruber, A., Larsson, R., Nygren, P., Bjorkholm, M. and Peterson, C. (1994). A non-p-glycoprotein-mediated mechanism of vincristine transport which is affected by resistance modifiers and present in chemosensitive cells. Leukemia, 8, 985-989.
50. Brophy, N. A., Marie, J. P., Rojas, V. A., Warnke, R. A., McFall, P. J., Smith, S. D. and Sikic, B. I. (1994). Mdr1 gene expression in childhood acute lymphoblastic leukemias and lymphomas: A critical evaluation by four techniques. Leukemia, 8, 327-335.
51. Herzog, C. E., Trepel, J. B., Mickley, L. A., Bates, S. E. and Fojo, A. T. (1992). Various methods of analysis of mdr-1/P-glycoprotein in human colon cancer cell lines. Journal of the National Cancer Institute, 84, 711-716.
52. Rao, V. V., Anthony, D. C. and Piwnica-Worms, D. (1994). MDR1 gene-specific monoclonal antibody C494 cross-reacts with pyruvate carboxylase. Cancer Research, 54, 1536-1541.
53. Georges, E., Bradley, G., Gariepy, J. and Ling, V. (1990). Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies. Proceedings of the National Academy of Sciences of the United States of America, 87, 152-156.
54. Chaudhary, P. M. and Roninson, I. B. (1991) Expression and activity of p-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell, 66, 85-94.
55. Drach, D., Zhao, S., Drach, J., Mahadevia, R., Gattringer, C., Huber, H. and Andreeff, M. (1992). Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood, 80, 2729-2734.
56. Marie, J.-P., Brophy, N. A., Ehsan, M. N., Aihara, Y., Mohamed, N. A., Cornbleet, J., Chao, N. J. and Sikic, B. I. (1992). Expression of multidrug resistance gene mdr1 mRNA in a subset of normal bone marrow cells. British Journal of Hematology, 81, 145-152.
57. Marie, J.-P., Legrand, O., Perrot, J.-Y., Chevillard, S., Huet, S. and Robert, J. (1997). Measuring multidrug resistance expression in human malignancies: Elaboration of consensus recommendations. Seminars in Hematology, 34, 63-71.
58. Hart, S. M., Ganeshaguru, K., Prentice, H. G., Hoffbrand, A. V. and Mehta, A. B. (1996). Multidrug resistance (MDR1) expression and function is decreased in advanced stage chronic lymphocytic leukaemia (CLL). Blood, 88, 363a.